Ipca Laboratories approves scheme to amalgamate Krebs Biochemicals by April 2026
Ipca Laboratories · Pharmaceuticals & Biotechnology
Key highlights
- Scheme of Amalgamation approved on June 26, 2026; effective from April 1, 2026, subject to approvals
- Share exchange ratio: 7 equity shares of Ipca (Re. 1 each) for every 200 shares of Krebs (Rs. 10 each)
- Pre-merger promoter holding 44.72%, public 55.28%; post-merger promoter 44.66%, public 55.34%
Why it's rated notable: The board approved a scheme to amalgamate the subsidiary Krebs Biochemicals into Ipca with no cash consideration and subject to approvals, and the filing states no value for the deal, so the subsidiary amalgamation rule keeps the level at medium at most.
Original filing
Board Meeting Outcome for Outcome Of Board Meeting
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Ipca Laboratories
- Acquisition / mergerNotableIpca Laboratories Ltd approves Scheme of Amalgamation with Krebs Biochemicals
Other acquisition / merger filings this fortnight
- IndiGrid Infrastructure Trust Q2 FY27 Earnings Conference Call Transcript Released
- Cubical Financial Services Ltd announces promoter reclassification post open offer
- Novus Loyalty Limited approves acquisition of AutoPe Payment Solutions via share swap
- Shish Industries Limited files Composite Scheme of Amalgamation proposal
- Jubilant Ingrevia Limited updates on acquisition of 40% stake in Zettaone Technologies
- NHC Foods approves quarter results, 99.98% Sachmaas Foods investment, two appointments
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.